Search Within

CTCR Scholars

Formats
  1. Meeting Abstract (875)
  2. Journal Article (566)
  3. Review (72)
  4. Research Letter (38)
  5. Editorial (29)
  6. Correspondence (25)
  7. Miscellaneous (17)
  8. Book Section (11)
  9. Guidelines (7)
  10. Conference Paper (4)
Groups
  1. Department of Medicine (1420)
  2. Hematologic Malignancies, Division of (1084)
  3. MSK Grad Students (1021)
  4. Center for Hematologic Malignancies (987)
  5. Master of Science in Clinical and Translational Cancer Research (986)
  6. Survivorship Research (920)

More Groups

People
  1. Sergio Giralt (555)
  2. Miguel-Angel Perales (411)
  3. Michael Scordo (387)
  4. Gunjan Shah (343)
  5. Sean Devlin (333)
  6. Parastoo Dahi (305)

More People

Years
  1. 2025 (101)
  2. 2024 (253)
  3. 2023 (261)
  4. 2022 (230)
  5. 2021 (166)
  6. 2020 (211)

More Years

Publications
  1. Blood (318)
  2. Biology of Blood and Marrow Transplantation (187)
  3. Journal of Clinical Oncology (144)
  4. Annals of Surgical Oncology (83)
  5. Bone Marrow Transplantation (65)
  6. Transplantation and Cellular Therapy (56)

More Publications

Publishers
  1. Elsevier Inc. (391)
  2. American Society of Hematology (372)
  3. American Society of Clinical Oncology (158)
  4. Nature Publishing Group (135)
  5. Springer (102)
  6. American Association for Cancer Research (65)

More Publishers

Results (1644)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disparities in microbiota diversity impacting non-European recipients of 8/8 HLA-matched unrelated donor transplantation
    Meeting Abstract

    Smith, N. G.; Fingrut, W. B.; Waters, N.; Piasevoli, K.; Fei, T.; Slingerland, J.; Peled, J. U.; Ponce, D. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Dhakal, B.; Yee, A. J.; Richardson, P. G.; Ailawadhi, S.; Chhabra, S.; Muchtar, E.; Berdeja, J. G.; Richard, S.; Matous, J.; Shah, U. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of immune reconstitution and their clinical significance in aggressive lymphoma treated with CAR-T therapy
    Meeting Abstract

    Luan, D. Y.; Dewolf, S.; Fei, T.; Raj, S. S.; Shah, G. L.; Lareau, C.; Alhomoud, M.; Salles, G.; Rivas-Delgado, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel (cilta-cel) versus standard of care for patients with lenalidomide-refractory multiple myeloma: Results from the phase 3 CARTITUDE-4 clinical trial
    Meeting Abstract

    Bar, N.; Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L. O.; Isufi, I.; Harrison, S. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • North American adult T-cell leukemia lymphoma has frequent mutations in CCR4 and responds in vitro to a small molecule CCR4 antagonist
    Meeting Abstract

    Liu, E.; Verma, A.; Pradhan, K.; Shah, U. A.; Shastri, A.; Guillen, E.; Sica, A.; Lauvau, G.; Janakiram, M.; Kassner, P. D.
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save